VisiRose, a Knoxville, TN-based clinical-stage biotechnology firm, raised $3M in Seed funding.
Backers weren’t disclosed.
The corporate intends to make use of the funds to help new initiatives, together with:
- Finishing a pre-investigational new drug (IND) submission assembly with the U.S. Meals and Drug Administration (FDA) for its Rose Bengal Photodynamic Antimicrobial Remedy (RB PDAT), a non-invasive, investigational therapy for infectious keratitis and different critical eye infections.
- Submitting an IND utility for investigational drug PV-305, concentrating on corneal blindness (RB) via photodynamic remedy (PDAT), and dealing towards its acceptance by the FDA.
- Manufacturing an preliminary medical provide of PV-305, enabling the corporate to provoke medical trials.
Led by CEO Dominic Rodrigues, VisiRose is leveraging a brand new ocular RB PDAT analysis from the College of Miami’s Bascom Palmer Eye Institute and Ophthalmic Biophysics Middle, in collaboration with Provectus Biopharmaceuticals (OTCQB: PVCT). On the coronary heart of its therapeutic platform is Provectus’s bioactive artificial small molecule, Rose Bengal Sodium (RBS), to deal with a variety of sight-threatening ocular situations with excessive unmet medical wants.
FinSMEs
16/01/2025
